OS Therapies
OSTXOS Therapies is a clinical-stage biopharmaceutical company dedicated to developing and commercializing immunotherapies and antibody-drug conjugates for Osteosarcoma and other solid tumors.
Earnings
Next report
Aug 17, 2026 (in a month)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
OS Therapies is a clinical-stage biopharmaceutical company dedicated to developing and commercializing immunotherapies and antibody-drug conjugates for Osteosarcoma and other solid tumors. The company's primary focus is addressing unmet medical needs in pediatric bone cancers through its lead immunotherapy candidate and a proprietary tunable drug conjugate platform. Its value proposition centers on utilizing genetically modified bacteria and next-generation linker technology to prevent cancer metastasis and recurrence.
A clinical-stage developer with Orphan Drug and Rare Pediatric Disease designations for its lead candidate, positioning it as a potential first-to-market provider for recurrent Osteosarcoma.
Questions, answered.
- What is OS Therapies's market cap?
- OS Therapies (OSTX) has a market capitalization of $76.6M and trades on XASE.
- Who are OS Therapies's competitors?
- OS Therapies's key competitors include AstraZeneca, Immunome, Inc., Instil Bio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does OS Therapies partner with?
- OS Therapies's notable partners include BlinkBio, Inc., Syngene International Limited, ReciBioPharma, and others.
- What subsidiaries does OS Therapies have?
- OS Therapies's subsidiaries include OS Animal Health.
- Where is OS Therapies headquartered?
- OS Therapies is headquartered in United States of America and employs approximately 4 people. It has been publicly traded since 2024.